Côte d'Ivoire is the largest economy in Francophone West Africa, with a GDP exceeding $75 billion and a population of approximately 28 million. Abidjan, the commercial capital, functions as the financial centre for the UEMOA (West African Economic and Monetary Union) zone — hosting the regional stock exchange, headquarters of major West African banks, and the African Development Bank. The country's position as the world's leading cocoa and cashew producer underpins a commodity-driven economy that is diversifying into financial services, retail, healthcare, and technology.
The pharmaceutical market in Côte d'Ivoire is regulated by the DPML (Direction de la Pharmacie du Médicament et des Laboratoires) under the Ministère de la Santé, with pharmaceutical activity further shaped by UEMOA harmonised regulations and the CEDEAO (ECOWAS) trade zone. The market is characterised by high pharmaceutical import dependency and significant public sector procurement through national health programmes. Research buyers in the Ivorian pharmaceutical and healthcare sector require partners with specific awareness of DPML licensing requirements, UEMOA regulatory frameworks, and the distinct public versus private channel dynamics.
Market research in Côte d'Ivoire is conducted primarily in French, with the country serving as the natural gateway for Francophone West Africa research programmes spanning Senegal, Mali, Burkina Faso, and Benin. The growing middle class in Abidjan and secondary cities is driving consumer market expansion across FMCG, financial services, digital, and healthcare categories. The right research partner must combine French-language fieldwork capability with global methodology standards and deep familiarity with the West African commercial environment.